-
2025 Thinheal in Shanghai CPHI Exhibition is Waiting for You
Hangzhou Thinheal Pharma-Tech Co., Ltd. will participate in the 23rd World Pharmaceutical Raw Materials China Exhibition (CPHI) in Shanghai, China on June 24 to 26, 2025. Booth number: W4G62.World Pharmaceutical Raw Materials China Exhibition(CPhI China) is a pharmaceutical exhibition that provides integrated solutions from pharmaceutical raw materials, contract customization, biopharmaceuticals, pharmaceutical machinery, packaging materials to laboratory instruments for professionals in the pharmaceutical industry, and expands global connections for domestic pharmaceutical companies.
The exhibition covers pharmaceutical manufacturers, distributors/import and export companies, pharmaceutical sales companies, biopharmaceutical and technology companies, pharmaceutical machinery, contract research and development and outsourcing, supervision/market, food and beverage/health food/beauty cosmetics companies, laboratory construction and instruments, cold chain and logistics, environmental protection and engineering, packaging materials/drug delivery system industry, pharmaceutical engineering, automation/robotics and other fields.
Our products include peptide APIs and peptide CRO and CDMO services, the production of cosmetic peptides, and the establishment of commercial peptide libraries. We are waiting for you at the Shanghai CPHI exhibition, booth number is W4G62.2025-05-09 162
-
Showcasing its strength at CPHI, it has won global attention.
Recently, Hangzhou Thinheal Pharma-Tech Co., Ltdmade a brilliant appearance at CPHI Worldwide, the international pharmaceutical ingredients trade fair in Germany, attracting widespread attention from numerous international industry partners with its technological strength and solutions in the fields of peptides and innovative drugs. During the exhibition, the Xinhai Pharmaceuticals team engaged in in-depth exchanges with company representatives, experts, scholars, and potential clients from Europe, North America, Asia, and other regions. The interactive atmosphere was lively, and a series of fruitful discussions and group photos not only captured moments of sincere cooperation but also laid a solid foundation for further expansion into international markets and the establishment of long-term partnerships.
2025-11-17 admin 44
-
Good News: Hangzhou ThinHeal Pharma's production base obtains drug production license
Recently, Hangzhou Xinhai Pharmaceutical Peptide Production Base, Zhejiang Peptide Rising Biopharmaceutical Co., Ltd. received a document issued by the Zhejiang Provincial Drug Administration. The inspection conclusion of the "Drug Production License" is that it meets the requirements, that is, the production quality management and compliance of Zhejiang Peptide Rising Biopharmaceutical Co., Ltd. have reached high domestic standards. It is conducive to Zhejiang Peptide Rising Biopharmaceutical to expand its global market share, especially in the EU market, enhance customer trust, promote international cooperation, and achieve the layout and growth goals of the global peptide drug market. With the growth of international market demand, Zhejiang Peptide Rising Biopharmaceutical Co., Ltd. can better respond to the needs of global customers.
2025-08-15 admin 91
-
Hangzhou Thinheal Pharma-Tech attended the 5th China Pharmaceutical R&D Innovation Summit
On September 10, the 2020 Big Health Industry High-Quality Development Conference and the 5th China Pharmaceutical R&D and Innovation Summit (PDI) kicked off grandly at the Chongqing Marriott Hotel. From September 10th to 11th, around the theme of "Formulation Innovation, Leading the Future", the conference was divided into the main forum on pharmaceutical formulation innovation and development, and sub-forums such as the discussion on key technologies for formulation development and the discussion on key technologies for sustained-release formulation development. Hundreds of experts and scholars from all over the country held heated discussions. In addition, Luo Ruichang, deputy general manager of our company, made a keynote report on "Discussion on Difficulties and Ideas in the Development of Peptide Products", pointing out that the market is huge and the advantages of peptide drugs are obvious, but the key to their consistency evaluation lies in the easily overlooked R&D technology.
2025-05-09 191
微信
微信